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To the Editor: Dermatologists perform a large number of cutaneous surgical procedures, 1,2 and a better understanding of the current volume of excisional and reconstructive surgery is needed, particularly as surgical consensus statements and guidelines are developed. Because patients increasingly see dermatologists as their primary skin cancer surgeons, 3 assessing data on dermatologists' contribution in this area is of great value, and these data have implications for residency training as well.
Medicare's Physician and Other Supplier Public Use File (PUF) for 2014, which includes detailed provider-level data for every claim, was used to assess the specialty of physicians engaged in excisional and reconstructive surgeries and the relative volume of surgical procedures they performed. This data set includes every separate charge to Medicare by every physician in the United States. 4, 5 Relevant codes were determined a priori on the basis of current procedural terminology (CPT) codes (Supplemental Table I ; available at http://www.jaad. org). Means and 95% confidence intervals were assessed for each of the variables of interest. One-way multivariate analysis of variance (MANOVA) was performed to assess for significant differences between mean values by categorical (specialist) grouping. Analysis of this public data source was exempt from institutional review board review. Statistical analyses were performed using Stata version 13 (Stata Corp, College Station, Texas).
The 2014 Medicare PUF includes a total of 9,316,307 unique combinations of provider and procedure code. Dermatologists account for 195,001 (2.1%) of the total. A total of 101,727 benign excisions and 341,637 malignant excisions were performed by dermatologists and billed to Medicare in 2014 (Table I) . Differences in mean values were statistically significant when assessed using MANOVA by specialty (P \.0001).
Dermatologists performed the vast majority of surgical procedures for benign and malignant excisions and cutaneous reconstructions that were billed to Medicare in 2014 (Fig 1) . Dermatologists represented the largest specialty group performing these surgeries and performed [15 times the number of intermediate and complex repairs as plastic and reconstructive surgeons, the next most productive group. Dermatologists also perform [4 times the number of local flaps and [6 times the number of grafts as plastic surgeons, all while averaging a significantly larger number of average per-physician yearly cases than any other specialist group (Table I) .
These findings have several limitations. The Medicare PUF data only include Medicare beneficiaries, and do not reflect any procedures performed for purely cosmetic reasons. Patients ineligible for Medicare would not be captured by these data, potentially limiting the generalizability of these findings.
These data expand on earlier studies using the most recent, comprehensive, and detailed database available, and suggest that the gap between dermatologists and other specialists in terms of surgical volume continues to widen.
1,2 Given these findings, increased exposure to surgical reconstruction should potentially be included in residency training in dermatology. This might also represent an opportunity for dermatologists to rethink the perception of the specialty among both nondermatologist physician colleagues and the general public. 
Trends in Medicare spending on topical immunomodulators and chemotherapies
To the Editor: Actinic keratoses (AKs) and in situ/superficial carcinomas are common and costly dermatologic conditions that account for $5.2 million visits and $920 million in annual spending. 1, 2 Topical therapies are often used as field therapy for these conditions. In this study, we evaluate recent national trends in topical therapy use and costs for precancerous and in situ/superficial carcinomas in the Medicare population. We evaluated population-based claims data from the Medicare Part D Prescriber Public Use File (PUF), which captures prescriptions for 70% of Medicare Part D subscribers between 2011 and 2015.
3 Topical therapies of interest included generic and branded topical formulations of fluorouracil, imiquimod, and ingenol mebutate. Diclofenac was excluded because of the difficulty distinguishing between oral and topical formulations. The Medicare PUF aggregates data across strengths and vehicles of any given medication at the brand name and generic name level. While specific brand name and generic drugs are separate in the database, data on specific strengths and vehicles (eg, 0.5% vs. 5% strength; cream vs. solution) among generic medications are lacking. This study was granted exemption by the Partners Healthcare Institutional Review Board.
Medicare spending was calculated using total spending figures. Patient out-of-pocket spending was calculated by multiplying beneficiary number and average beneficiary cost shares, which represent average patient costs not reimbursed by a third party. The increase in Medicare spending and patient out-of-pocket costs was then compared to the increase in total beneficiary count. The Medicare PUF provided a weighted average cost per unit for each medication, which was calculated at the level of each formulation and strength and weighted by the number of claims. 3 Results were adjusted for inflation and reported in 2015 dollars. 4 Total Medicare spending on topical treatments for AKs was $585.3 million over the study period, and increased 32% ($101.1 to $133.5 million) between 2011 and 2015 (Fig 1) . Total patient out-of-pocket costs were $87.8 million, an increase of 52.5% 
